KDR and glioblastoma: So far, many aspects of the role of EndoMT in cancer remain largely unknown, but two hallmark publications in 2018 suggested that EndoMT contributes to phenomena such as resistance to radiotherapy in lung cancer and resistance to conventional antiangiogenic therapies that target VEGFR2 in glioblastoma [91,92].